Misplaced Pages

An emerging infectious disease (EID) is an infectious disease whose incidence has increased recently (in the past 20 years), and could increase in the near future. The minority that are capable of developing efficient transmission between humans can become major public and global concerns as potential causes of epidemics or pandemics. Their many impacts can be economic and societal, as well as clinical. EIDs have been increasing steadily since at least 1940.

For every decade since 1940, there has been a consistent increase in the number of EID events from wildlife-related zoonosis. Human activity is the primary driver of this increase, with loss of biodiversity a leading mechanism.

Emerging infections account for at least 12% of all human pathogens. EIDs can be caused by newly identified microbes, including novel species or strains of virus (e.g. novel coronaviruses, ebolaviruses, HIV). Some EIDs evolve from a known pathogen, as occurs with new strains of influenza. EIDs may also result from spread of an existing disease to a new population in a different geographic region, as occurs with West Nile fever outbreaks. Some known diseases can also emerge in areas undergoing ecologic transformation (as in the case of Lyme disease). Others can experience a resurgence as a re-emerging infectious disease, like tuberculosis (following drug resistance) or measles. Nosocomial (hospital-acquired) infections, such as methicillin-resistant Staphylococcus aureus are emerging in hospitals, and are extremely problematic in that they are resistant to many antibiotics. Of growing concern are adverse synergistic interactions between emerging diseases and other infectious and non-infectious conditions leading to the development of novel syndemics.

Many EID are zoonotic, deriving from pathogens present in animals, with only occasional cross-species transmission into human populations. For instance, most emergent viruses are zoonotic (whereas other novel viruses may have been circulating in the species without being recognized, as occurred with hepatitis C).

History of the concept of emerging infectious diseases

The French doctor Charles Anglada (1809–1878) wrote a book in 1869 on extinct and new diseases. He did not distinguish infectious diseases from others (he uses the terms reactive and affective diseases, to mean diseases with an external or internal cause, more or less meaning diseases with or without an observable external cause). He writes in the introduction:

A widely held opinion among physicians admits the invariability of pathologies. All the illnesses which have existed or which have an outbreak around us are categorized according to arrested and preconceived types, and must enter one way or the other into the frameworks established by the nosologists. History and observation protest wildly against this prejudice, and this is what they teach: Diseases which have disappeared and whose traces are confined to the archives of science, are followed by other diseases, unknown to the contemporary generation, and which come for the first time to assert their rights. In other words, there are extinct and new diseases.

Charles Nicolle, laureate of the Nobel Prize in Physiology or Medicine elaborated the concept of emergence of diseases in his 1930 book Naissance, vie et mort des maladies infectieuses (Birth, Life and Death of Infectious Diseases), and later in Destin des maladies infectieuses (Fate of Infectious Diseases) published in 1933 which served as lecture notes for his teaching of a second year course at the Collège de France. In the introduction of the book he sets out the program of the lectures:

It is this historical existence, this destiny that will be the subject of our talks. I will have to answer, to the extent that our current knowledge allows, questions that you have asked yourself, that every thoughtful or simply curious mind asks: have the infectious diseases that we observe today always existed? Or have some of them appeared in the course of history? Can we assume that new ones will appear? Can we assume that some of these diseases will disappear? Have some of them already disappeared? Finally, what will become of humanity and domestic animals if, as a result of more and more frequent contacts between people, the number of infectious diseases continues to increase?

The term emerging disease has been in use in scientific publications since the beginning of the 1960s at least and is used in the modern sense by David Sencer in his 1971 article "Emerging Diseases of Man and Animals" where in the first sentence of the introduction he implicitly defines emerging diseases as "infectious diseases of man and animals currently emerging as public health problems" and as a consequence also includes re-emerging diseases:

Infectious diseases of man and animals currently emerging as public health problems include some old acquaintances and some that are new in respect to identity or concept.

He also notes that some infectious agents are newly considered as diseases because of changing medical technologies:

But there are also many familiar organisms formerly considered nonpathogenic that are now associated with nosocomial infections, use of artificial kidneys, and the acceptance or rejection of organ transplants, for example.

He concludes the introduction with a word of caution:

And so infectious disease, one of man's oldest enemies, survives as an adversary that calls forth our best efforts.

However, to many people in the 1960s and 1970s the emergence of new diseases appeared as a marginal problem, as illustrated by the introduction to the 1962 edition of Natural History of Infectious Disease by Macfarlane Burnet:

to write about infectious disease is almost to write of something that has passed into history

as well as the epilogue of the 1972 edition:

On the basis of what has happened in the last thirty years, can we forecast any likely developments for the 1970s? If for the present we retain a basic optimism and assume no major catastrophes occur the most likely forecast about the future of infectious disease is that it will be very dull. There may be some wholly unexpected emergence of a new and dangerous infectious disease, but nothing of the sort has marked the past fifty years.

The concept gained more interest at the end of the 1980s as a reaction to the AIDS epidemic. On the side of epistemology, Mirko Grmek worked on the concept of emerging diseases while writing his book on the history of AIDS and later in 1993 published an article about the concept of emerging disease as a more precise notion than the term "new disease" that was mostly used in France at that time to qualify AIDS among others.

Also under the shock of the emergence of AIDS, epidemiologists wanted to take a more active approach to anticipate and prevent the emergence of new diseases. Stephen S. Morse from The Rockefeller University in New York was chair and principal organizer of the NIAID/NIH Conference "Emerging Viruses: The Evolution of Viruses and Viral Diseases" held 1–3 May 1989 in Washington, DC. In the article summarizing the conference the authors write:

Challenged by the sudden appearance of AIDS as a major public health crisis jointly sponsored the conference "Emerging Viruses: The Evolution of Viruses and Viral Diseases" It was convened to consider the mechanisms of viral emergence and possible strategies for anticipating, detecting, and preventing the emergence of new viral diseases in the future.

They further note:

Surprisingly, most emergent viruses are zoonotic, with natural animal reservoirs a more frequent source of new viruses than is the sudden evolution of a new entity. The most frequent factor in emergence is human behavior that increases the probability of transfer of viruses from their endogenous animal hosts to man.

In a 1991 paper Morse underlines how the emergence of new infectious diseases (of which the public became aware through the AIDS epidemic) is the opposite of the then generally expected retreat of these diseases:

The striking successes achieved with antibiotics, together with widespread application of vaccines for many previously feared viral diseases, made it appear to many physicians and the public that infectious diseases were retreating and would in time be fully conquered. Although this view was disputed by virologists and many specialists in infectious diseases, it had become a commonplace to suggest that infectious diseases were about to become a thing of the past .

As a direct consequence of the 1989 conference on emerging viruses, the Institute Of Medicine convened in February 1991 the 19-member multidisciplinary Committee on Emerging Microbial Threats to Health, co-chaired by Joshua Lederberg and Robert Shope, to conduct an 18-month study. According to the report produced by the committee in 1992, its charge "was to identify significant emerging infectious diseases, determine what might be done to deal with them, and recommend how similar future threats might be confronted to lessen their impact on public health." The report recommended setting up a surveillance program to recognize emerging diseases and proposed methods of intervention in case an emergent disease was discovered.

A well-designed, well-implemented surveillance program can detect unusual clusters of disease, document the geographic and demographic spread of an outbreak, and estimate the magnitude of the problem. It can also help to describe the natural history of a disease, identify factors responsible for emergence, facilitate laboratory and epidemiological research, and assess the success of specific intervention efforts.

The proposed interventions were based on the following: the U.S. public health system, research and training, vaccine and drug development, vector control, public education and behavioral change. A few years after the 1989 Emerging Viruses conference and the 1992 IOM report, the Program for Monitoring Emerging Diseases (ProMED) was formed by a group of scientists as a follow-up in 1994 and the Centres for Disease Control (CDC) launched the Emerging Infectious Diseases journal in 1995.

A decade later the IOM convened the Committee on Emerging Microbial Threats to Health in the 21st Century which published its conclusions in 2003.

In April 2000 the WHO organized a meeting on Global Outbreak Alert and Response, which was the founding act of the Global Outbreak Alert and Response Network.

In 2014, the Western African Ebola virus epidemic demonstrated how ill-prepared the world was to handle such an epidemic. In response, the Coalition for Epidemic Preparedness Innovation was launched at the World Economic Forum in 2017 with the objective of accelerating the development of vaccines against emerging infectious diseases to be able to offer them to affected populations during outbreaks. CEPI promotes the idea that a proactive approach is required to "create a world in which epidemics are no longer a threat to humanity".

Classification

One way to classify emerging infections diseases is by time and how humans were involved in the emergence:

• Newly emerging infectious diseases – diseases that were not previously described in humans, such as HIV/AIDS
• Re-emerging infectious diseases – diseases that have spread to new places or which previous treatments no longer control, such as methicillin-resistant Staphylococcus aureus
• Deliberately emerging infectious diseases – diseases created by humans for bioterrorism
• Accidentally emerging infectious diseases – diseases created or spread unintentionally by humans, such as vaccine-derived poliovirus

Contributing factors

The 1992 IOM report distinguished 6 factors contributing to emergence of new diseases (Microbial adaptation and change; Economic development and land use; Human demographics and behavior; International travel and commerce; Technology and industry; Breakdown of public health measures) which were extended to 13 factors in the 2003 report (Chapter 3 of the report detailing each of them)

• Microbial adaptation and change
• Human susceptibility to infection
• Climate and weather
• Changing ecosystems
• Human demographics and behavior
• Economic development and land use
• International travel and commerce
• Technology and industry
• Breakdown of public health measures
• Poverty and social inequality
• War and famine
• Lack of political will
• Intent to harm

Their classification serves as a basis for many others. The following table gives examples for different factors:

Emerging Infectious Diseases between Humans and Animals

Emerging infectious diseases between human, animal have become a significant concern in recent years, playing a crucial role in the occurrence and spread of diseases. Human population growth, increased proximity to wildlife, and climate change have created favorable conditions for the transmission of zoonotic diseases, leading to outbreaks such as Zika, Ebola, and COVID-19. The One Health approach, which integrates animal, human, and environmental health, has emerged as a crucial tool for monitoring and mitigating the spread of infectious diseases.

Zoonotic diseases, originating from animal sources, pose a significant threat to human health. Up to 75% of emerging infectious diseases are zoonotic, originating from viruses and other pathogens that are transmitted from animals to humans. Understanding the mechanisms of transmission, the role of wildlife trade, and the importance of surveillance and early detection is crucial for mitigating the impact of zoonotic diseases on human health. Surveillance efforts involving wastewater have been identified as valuable tools for detecting early warning signs of disease emergence and providing timely interventions.

List

NIAID list of Biodefense and Emerging Infectious Diseases

The U.S. National Institute of Allergy and Infectious Diseases (NIAID) maintains a list of Biodefense and Emerging Infectious Diseases. The list is categorized by biodefense risk, which is mostly based on biological warfare and bioterrorism considerations. As of 2004, it recognized the following emerging and re-emerging diseases.

• Acanthamebiasis
• Australian bat lyssavirus
• Babesia, atypical
• Bartonella henselae
• Coronaviruses, including SARS coronavirus
• Ehrlichiosis
• Encephalitozoon cuniculi
• Encephalitozoon hellem
• Enterocytozoon bieneusi
• Helicobacter pylori
• Hendra virus (equine morbilli virus)
• Hepatitis C
• Hepatitis E
• Human herpesvirus 8
• Human herpesvirus 6
• Lyme borreliosis
• Microsporidia
• Parvovirus B19

Re-emerging:

• Coccidioides immitis
• Enterovirus 71
• Prion diseases
• Streptococcus, group A
• Staphylococcus aureus

Diseases with bioterrorism potential, CDC category A (most dangerous):

• Anthrax
• Clostridium botulinum
• Tularemia
• Smallpox and other pox viruses
• Viral hemorrhagic fevers
  • Arenaviruses: Lymphocytic choriomeningitis (LCM), Junin virus, Machupo virus, Guanarito virus, Lassa fever
  • Bunyaviruses: Hantaviruses, Rift Valley Fever, Crimean-Congo hemorrhagic fever virus
  • Flaviviruses: Dengue
  • Filoviruses: Ebola, Marburg
• Yersinia pestis

Diseases with bioterrorism potential, CDC category B:

• Brucella species (brucellosis)
• Burkholderia pseudomallei (melioidosis)
• Burkholderia mallei (glanders)
• Coxiella burnetii (Q fever)
• Epsilon toxin of Clostridium perfringens
• Food-borne and Water-borne Pathogens
  • Bacteria
    • Campylobacter jejuni
    • Diarrheagenic E. coli
    • Listeria monocytogenes
    • Pathogenic vibrios
    • Salmonella
    • Shigella species
    • Yersinia enterocolitica
  • Protozoa
    • Cryptosporidium parvum
    • Cyclospora cayetanensis
    • Entamoeba histolytica
    • Giardia lamblia
    • Toxoplasma
  • Fungi
    • Microsporidia
  • Viruses:
    • Caliciviruses
    • Hepatitis A
• Mosquito-borne encephalitis viruses
  • California encephalitis
  • Eastern equine encephalitis (EEE)
  • Japanese encephalitis virus (JE)
  • Kyasanur Forest virus
  • LaCrosse virus (LACV)
  • Venezuelan equine encephalitis (VEE)
  • Western equine encephalitis (WEE)
  • West Nile virus (WNV)
  • Yellow fever
• Ricin toxin (from Ricinus communis)
• Staphylococcal enterotoxin B
• Typhus fever (Rickettsia prowazekii)

Diseases with bioterrorism potential, CDC category C (least dangerous):

• Influenza
• Multidrug-resistant tuberculosis (MDR-TB)
• Nipah virus
• Rabies
• SARS coronavirus
• Tick-borne encephalitis virus
• Tick-borne hemorrhagic fever viruses
• Other hantaviruses
• Other rickettsias

Since 2004, NIAID has added to its biodefense emerging pathogen list:

• Yersinia pestis (plague, category A)
• Chapare virus (category A areanavirus)
• Lujo (category A arenavirus)
• Chlamydia psittaci (category B)
• Naegleria fowleri (category B)
• Balamuthia mandrillaris (category B)
• St. Louis encephalitis virus (SLEV, category B)
• Tick-borne hemorrhagic fever viruses (category C)
  • Bunyaviruses: Severe Fever with Thrombocytopenia Syndrome virus (SFTSV), Heartland virus
  • Flaviviruses: Omsk Hemorrhagic Fever virus, Alkhurma virus, Kyasanur Forest virus (reclassified from B to C)
• Powassan virus (Deer Tick virus, category C)
• Chikungunya virus (category B)
• Coccidioides species (category C)
• Human coronavirus HKU1 (category C)
• Middle East respiratory syndrome coronavirus (category C)
• Anaplasmosis
• Aspergillus
• BK virus
• Bordetella pertussis
• Borrelia miyamotoi
• Clostridioides difficile
• Cryptococcus gattii
• Enterococcus faecium
• Enterococcus faecalis
• Enterovirus 68
• JC virus
• Leptospirosis
• Measles
• Mucormycosis
• Mumps virus
• Poliovirus
• Zika virus (category B)

WHO list of most important emerging infectious diseases

In December 2015, the World Health Organization held a workshop on prioritization of pathogens "for accelerated R&D for severe emerging diseases with potential to generate a public health emergency, and for which no, or insufficient, preventive and curative solutions exist." The result was a list containing the following six diseases:

• Crimean–Congo hemorrhagic fever
• Filovirus diseases (Ebola virus disease and Marburg virus disease)
• Highly pathogenic emerging Coronaviruses relevant to humans (MERS and SARS)
• Lassa fever
• Nipah virus infection
• Rift Valley fever

These were selected based on the following measures:

1. Human transmissibility (including population immunity, behavioural factors, etc.)
2. Severity or case fatality rate
3. Spillover potential
4. Evolutionary potential
5. Available countermeasures
6. Difficulty of detection or control
7. Public health context of the affected area(s)
8. Potential scope of outbreak (risk of international spread)
9. Potential societal impacts

Newly reported infectious diseases

In 2007 Mark Woolhouse and Eleanor Gaunt established a list of 87 human pathogens first reported in the period between 1980 and 2005. These were classified according to their types.

Major outbreaks

The following table summarizes the major outbreaks since 1998 caused by emerging or re-emerging infectious diseases.

Methicillin-resistant Staphylococcus aureus

Methicillin-resistant Staphylococcus aureus (MRSA) evolved from methicillin-susceptible Staphylococcus aureus (MSSA), otherwise known as common S. aureus. Many people are natural carriers of S. aureus, without being affected in any way. MSSA was treatable with the antibiotic methicillin until it acquired the gene for antibiotic resistance. Through genetic mapping of various strains of MRSA, scientists have found that MSSA acquired the mecA gene in the 1960s, which accounts for its pathogenicity, before this it had a predominantly commensal relationship with humans. It is theorized that when this S. aureus strain that had acquired the mecA gene was introduced into hospitals, it came into contact with other hospital bacteria that had already been exposed to high levels of antibiotics. When exposed to such high levels of antibiotics, the hospital bacteria suddenly found themselves in an environment that had a high level of selection for antibiotic resistance, and thus resistance to multiple antibiotics formed within these hospital populations. When S. aureus came into contact with these populations, the multiple genes that code for antibiotic resistance to different drugs were then acquired by MRSA, making it nearly impossible to control. It is thought that MSSA acquired the resistance gene through the horizontal gene transfer, a method in which genetic information can be passed within a generation, and spread rapidly through its own population as was illustrated in multiple studies. Horizontal gene transfer speeds the process of genetic transfer since there is no need to wait an entire generation time for gene to be passed on. Since most antibiotics do not work on MRSA, physicians have to turn to alternative methods based in Darwinian medicine. However, prevention is the most preferred method of avoiding antibiotic resistance. By reducing unnecessary antibiotic use in human and animal populations, antibiotics resistance can be slowed.

Scientific Advisory Group for Origins of Novel Pathogens

On 16 July 2021, the Director-General of WHO announced the formation of the Scientific Advisory Group for Origins of Novel Pathogens (SAGO), which is to be a permanent advisory body of the organisation. The Group was formed with a broad objective to examine emerging infectious diseases, including COVID-19. According to the WHO Director-General, "SAGO will play a vital role in the next phase of studies into the origins of SARS-CoV-2, as well as the origins of future new pathogens."

See also

• Disease X
• Epidemiological transition
• Globalization and disease
• Pandemic prevention

References

1. Paules CI, Eisinger RW, Marston HD, Fauci AS (2017-12-05). "What Recent History Has Taught Us About Responding to Emerging Infectious Disease Threats". Annals of Internal Medicine. 167 (11): 805–811. doi:10.7326/M17-2496. ISSN 0003-4819. PMID 29132162. S2CID 36800971.
2. "Emerging Infectious Diseases - NIOSH Workplace Safety and Health Topic". www.cdc.gov. Centers for Disease Control and Prevention. 17 October 2018. Archived from the original on 18 April 2020.
3. A brief guide to emerging infectious diseases and zoonoses. WHO Regional Office for South-East Asia. 2014. hdl:10665/204722. ISBN 9789290224587.
4. ^ Woolhouse ME, Gowtage-Sequeria S (2005). "Host Range and Emerging and Reemerging Pathogens". Emerging Infectious Diseases. 11 (12): 1842–7. doi:10.3201/eid1112.050997. PMC 3367654. PMID 16485468.
5. Morens DM, Fauci AS (2013). "Emerging infectious diseases: threats to human health and global stability". PLOS Pathogens. 9 (7): e1003467. doi:10.1371/journal.ppat.1003467. PMC 3701702. PMID 23853589.
6. Jones K (2008). "Global trends in emerging infectious diseases". Nature. 451 (7181): 990–993. Bibcode:2008Natur.451..990J. doi:10.1038/nature06536. PMC 5960580. PMID 18288193.
7. Felicia K (2010). "Impacts of biodiversity on the emergence and transmission of infectious diseases". Nature. 468 (7324): 647–652. Bibcode:2010Natur.468..647K. doi:10.1038/nature09575. PMC 7094913. PMID 21124449.
8. Taylor L., et al. (2001). "Risk factors for human disease emergence". Philosophical Transactions of the Royal Society B. 356 (1411): 983–9. doi:10.1098/rstb.2001.0888. PMC 1088493. PMID 11516376.
9. Fauci AS (2005). "Emerging and reemerging infectious diseases: the perpetual challenge". Academic Medicine. 80 (12): 1079–85. doi:10.1097/00001888-200512000-00002. PMID 16306276. S2CID 17293745.
10. Kilpatrick AM, Dobson AD, Levi T, et al. (2017). "Lyme disease ecology in a changing world: consensus, uncertainty and critical gaps for improving control". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 372 (1722): 20160117. doi:10.1098/rstb.2016.0117. PMC 5413869. PMID 28438910.
11. Miquel Porta, Sander Greenland, Miguel Hernán, Isabel dos Santos Silva, John M. Last, eds. (2014). A Dictionary of Epidemiology. Oxford University Press. p. 92. ISBN 978-0-19-997673-7.
12. Fraser-bell C (2019). "Global Re-emergence of Measles - 2019 update". Global Biosecurity. 1 (3). doi:10.31646/gbio.43. ISSN 2652-0036.
13. Witte W (1997). "Increasing incidence and widespread dissemination of methicillin-resistant Staphylococcus aureus (MRSA) in hospitals in central Europe, with special reference to German hospitals". Clinical Microbiology and Infection. 3 (4): 414–22. doi:10.1111/j.1469-0691.1997.tb00277.x. PMID 11864151.
14. ^ "The 2019–2020 Novel Coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2) Pandemic: A Joint American College of Academic International Medicine‑World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group Consensus Paper". ResearchGate. Retrieved May 16, 2020.
15. Houghton M (November 2009). "The long and winding road leading to the identification of the hepatitis C virus". Journal of Hepatology. 51 (5): 939–48. doi:10.1016/j.jhep.2009.08.004. PMID 19781804.
16. Anglada C (1869). Étude sur les maladies éteintes et les maladies nouvelles, pour servir à l'histoire des évolutions séculaires de la pathologie. Paris: J.-B. Baillière et fils.
17. Nicolle C (2013) . Destin des maladies infectieuses. Presses Électroniques de France. ISBN 979-10-223-0029-2.
18. ^ Ndow G, Ambe JR, Tomori O (2019-03-20). "Emerging Infectious Diseases: A Historical and Scientific Review". Socio-cultural Dimensions of Emerging Infectious Diseases in Africa. pp. 31–40. doi:10.1007/978-3-030-17474-3_3. ISBN 978-3-030-17473-6. PMC 7123112.
19. Sencer DJ (October 1971). "Emerging Diseases of Man and Animals". Annual Review of Microbiology. 25 (1): 465–486. doi:10.1146/annurev.mi.25.100171.002341. ISSN 0066-4227. PMID 5005031.
20. Burnet, F. M. (Frank Macfarlane), Sir, 1899-1985. (1962). Natural history of infectious disease. White, David O. (3rd ed.). Cambridge : University Press. ISBN 0-521-04392-1.{{cite book}}: CS1 maint: multiple names: authors list (link) CS1 maint: numeric names: authors list (link)
21. Burnet, F. M. (Frank Macfarlane), Sir, 1899-1985. (1972). Natural history of infectious disease. White, David O. (4th ed.). Cambridge : University Press. ISBN 0-521-08389-3. OCLC 545868.{{cite book}}: CS1 maint: multiple names: authors list (link) CS1 maint: numeric names: authors list (link)
22. Grmek, Mirko Dražen, (1924-2000) (1995). Histoire du sida début et origine d'une pandémie actuelle. Impr. BCI) (Nouv. édition revue et augmentée ed.). : Payot et Rivages. ISBN 2-228-88908-3. OCLC 708336637.{{cite book}}: CS1 maint: multiple names: authors list (link) CS1 maint: numeric names: authors list (link)
23. Grmek M (1993). "Le concept de maladie émergente". History and Philosophy of the Life Sciences. 15 (3): 281–296. JSTOR 23331726.
24. Morse SS, Schluederberg A (1990-07-01). "Emerging Viruses: The Evolution of Viruses and Viral Diseases". The Journal of Infectious Diseases. 162 (1): 1–7. doi:10.1093/infdis/162.1.1. ISSN 0022-1899. PMID 2113071.
25. Morse SS (1991). "Emerging Viruses: Defining the Rules for Viral Traffic". Perspectives in Biology and Medicine. 34 (3): 387–409. doi:10.1353/pbm.1991.0038. ISSN 1529-8795. PMID 2067933. S2CID 46237193.
26. ^ Institute of Medicine (US) Committee on Emerging Microbial Threats to Health (1992). Lederberg J, Shope RE, Oaks SC (eds.). Emerging Infections: Microbial Threats to Health in the United States. Washington (DC): National Academies Press (US). ISBN 978-0-309-04741-8. PMID 25121245.
27. Morse SS (2014-02-07). "Public Health Disease Surveillance Networks". Microbiology Spectrum. 2 (1): OH-0002-2012. doi:10.1128/microbiolspec.OH-0002-2012. ISBN 9781555818425. ISSN 2165-0497. PMID 26082122.
28. ^ Microbial threats to health : emergence, detection, and response. Smolinski, Mark S., Hamburg, Margaret A., Lederberg, Joshua., Institute of Medicine (U.S.). Committee on Emerging Microbial Threats to Health in the 21st Century. Washington, D.C.: National Academies Press. 2003. ISBN 0-309-50730-8. OCLC 53981415. PMID 25057653.{{cite book}}: CS1 maint: others (link)
29. Organization WH (26–28 April 2000). "Global outbreak alert and response" (PDF). WHO. Geneva, Switzerland. hdl:10665/66750. Retrieved 10 September 2020.
30. "A brief history of vaccines and how they changed the world". World Economic Forum. Retrieved 2020-04-30.
31. "Creating a world in which epidemics are no longer a threat to humanity" (PDF). WHO. Retrieved 27 January 2021.
32. Morens DM, Fauci AS (2020-09-03). "Emerging Pandemic Diseases: How We Got to COVID-19". Cell. 182 (5): 1077–1092. doi:10.1016/j.cell.2020.08.021. ISSN 0092-8674. PMC 7428724. PMID 32846157.
33. Plaza M., Paladino L., Opara I. N., Firstenberg M. S., Wilson B., Papadimos T. J., Stawicki S. P. The use of distributed consensus algorithms to curtail the spread of medical misinformation. Int J Acad Med 2019 ; 5:93-99.
34. Patricia CR, Zulay JP, Carlos RL, et al. (2019). "The Influence of Antivaccination Movements on the Re-emergence of Measles". Journal of Pure and Applied Microbiology. 13 (1): 127–132. doi:10.22207/JPAM.13.1.13.
35. Smith KM, Anthony SJ, Switzer WM, et al. (2012). "Zoonotic viruses associated with illegally imported wildlife products". PLOS ONE. 7 (1): e29505. Bibcode:2012PLoSO...729505S. doi:10.1371/journal.pone.0029505. PMC 3254615. PMID 22253731.
36. Smith KF, Schloegel LM, Rosen GE (2012). "Wildlife Trade and the Spread of Disease". In Aguirre AA, Ostfeld R, Daszak P (eds.). New Directions in Conservation Medicine: Applied Cases of Ecological Health. Oxford University Press. pp. 151–163. ISBN 978-0-19-990905-6.
37. Chan JF, To KK, Tse H, et al. (2013). "Interspecies transmission and emergence of novel viruses: lessons from bats and birds". Trends in Microbiology. 21 (10): 544–55. doi:10.1016/j.tim.2013.05.005. PMC 7126491. PMID 23770275.
38. LeBreton M, Pike BL, Saylors KE, et al. (2012). "Bushmeat and Infectious Disease Emergence". In A. Alonso Aguirre, Richard Ostfeld, Peter Daszak (eds.). New Directions in Conservation Medicine: Applied Cases of Ecological Health. Oxford University Press. pp. 164–178. ISBN 978-0-19-990905-6.
39. Murray KA, Allen T, Loh E, et al. (2015). "Emerging Viral Zoonoses from Wildlife Associated with Animal-Based Food Systems: Risks and Opportunities". In Russell MJ, Doyle MP (eds.). Food Safety Risks from Wildlife. Springer. pp. 31–57. doi:10.1007/978-3-319-24442-6_2. ISBN 978-3-319-24442-6. S2CID 133576419.
40. Kurpiers LA, Schulte-Herbrüggen B, Ejotre I, et al. (2016). "Bushmeat and Emerging Infectious Diseases: Lessons from Africa". In Angelici F (ed.). Problematic Wildlife: A Cross-Disciplinary Approach. Springer. pp. 31–57. doi:10.1007/978-3-319-22246-2_24. ISBN 978-3-319-22246-2. S2CID 85916327.
41. ^ Leifels M, Khalilur Rahman O, Sam IC, Cheng D, Chua FJ, Nainani D, Kim SY, Ng WJ, Kwok WC, Sirikanchana K, Wuertz S, Thompson J, Chan YF (2022-10-30). "The one health perspective to improve environmental surveillance of zoonotic viruses: lessons from COVID-19 and outlook beyond". ISME Communications. 2 (1): 107. doi:10.1038/s43705-022-00191-8. ISSN 2730-6151. PMC 9618154. PMID 36338866.
42. ^ "Health Ecology and Disease Transmission" (PDF).
43. Nichol AA (2024-02-01). "Emerging Infectious Diseases at the Intersections of Human, Animal, and Environmental Health". AMA Journal of Ethics. 26 (2): 99–102. doi:10.1001/amajethics.2024.99. ISSN 2376-6980. PMID 38306198.
44. "NIAID Emerging Infectious Diseases/ Pathogens | NIH: National Institute of Allergy and Infectious Diseases". Niaid.nih.gov. 2018-07-26. Retrieved 2020-05-24.
45. "NIAID Emerging Infectious Diseases/ Pathogens". www.niaid.nih.gov. NIH - National Institute of Allergy and Infectious Diseases. 26 July 2018. Archived from the original on 18 April 2020.
46. "Blueprint for R&D preparedness and response to public health emergencies due to highly infectious pathogens". www.who.int. Archived from the original on 28 April 2020.
47. Woolhouse M, Gaunt E (January 2007). "Ecological Origins of Novel Human Pathogens". Critical Reviews in Microbiology. 33 (4): 231–242. doi:10.1080/10408410701647560. ISSN 1040-841X. PMID 18033594. S2CID 19213392.
48. "Emerging infections: how and why they arise". 27 February 2019.
49. Gerrard SR, Li L, Barrett AD, Nichol ST (2004-08-15). "Ngari Virus Is a Bunyamwera Virus Reassortant That Can Be Associated with Large Outbreaks of Hemorrhagic Fever in Africa". Journal of Virology. 78 (16): 8922–8926. doi:10.1128/JVI.78.16.8922-8926.2004. ISSN 0022-538X. PMC 479050. PMID 15280501.
50. Hontz RD, Guevara C, Halsey ES, Silvas J, Santiago FW, Widen SG, Wood TG, Casanova W, Vasilakis N, Watts DM, Kochel TJ (May 2015). "Itaya virus, a Novel Orthobunyavirus Associated with Human Febrile Illness, Peru". Emerging Infectious Diseases. 21 (5): 781–8. doi:10.3201/eid2105.141368. ISSN 1080-6040. PMC 4412221. PMID 25898901.
51. Law YH (2018-04-16). "Rare human outbreak of monkey malaria detected in Malaysia". Nature: d41586–018–04121–4. doi:10.1038/d41586-018-04121-4. ISSN 0028-0836.
52. Wu Z, Yang L, Yang F, Ren X, Jiang J, Dong J, Sun L, Zhu Y, Zhou H, Jin Q (June 2014). "Novel Henipa-like Virus, Mojiang Paramyxovirus, in Rats, China, 2012". Emerging Infectious Diseases. 20 (6): 1064–6. doi:10.3201/eid2006.131022. ISSN 1080-6040. PMC 4036791. PMID 24865545.
53. To KK, Tsang AK, Chan JF, Cheng VC, Chen H, Yuen KY (March 2014). "Emergence in China of human disease due to avian influenza A(H10N8) – Cause for concern?". Journal of Infection. 68 (3): 205–215. doi:10.1016/j.jinf.2013.12.014. PMID 24406432.
54. Jiang JF, Jiang RR, Chang QC, Zheng YC, Jiang BG, Sun Y, Jia N, Wei R, Liu HB, Huo QB, Wang H (2018-08-02). Vinetz JM (ed.). "Potential novel tick-borne Colpodella species parasite infection in patient with neurological symptoms". PLOS Neglected Tropical Diseases. 12 (8): e0006546. doi:10.1371/journal.pntd.0006546. ISSN 1935-2735. PMC 6071948. PMID 30071019.
55. Kalra S., Kelkar D., Galwankar S. C., Papadimos T. J., Stawicki S. P., Arquilla B., Hoey B. A., Sharpe R. P., Sabol D., Jahre J. A. The emergence of Ebola as a global health security threat: From 'lessons learned' to coordinated multilateral containment efforts. J Global Infect Dis 2014 ; 6:164–77.
56. Sikka V, Chattu VK, Popli RK, Galwankar SC, Kelkar D, Sawicki SG, Stawicki SP, Papadimos TJ (11 February 2016). "The emergence of zika virus as a global health security threat: A review and a consensus statement of the INDUSEM Joint working Group (JWG)". Journal of Global Infectious Diseases. 8 (1): 3–15. doi:10.4103/0974-777X.176140. ISSN 0974-8245. PMC 4785754. PMID 27013839.
57. Edridge AW, Deijs M, Namazzi R, Cristella C, Jebbink MF, Maurer I, Kootstra NA, Buluma LR, van Woensel JB, de Jong MD, Idro R (2019-01-01). "Novel Orthobunyavirus Identified in the Cerebrospinal Fluid of a Ugandan Child With Severe Encephalopathy". Clinical Infectious Diseases. 68 (1): 139–142. doi:10.1093/cid/ciy486. ISSN 1058-4838. PMC 6293039. PMID 29893821.
58. Andonov A, Robbins M, Borlang J, Cao J, Hatchette T, Stueck A, Deschambault Y, Murnaghan K, Varga J, Johnston L (2019-08-09). "Rat Hepatitis E Virus Linked to Severe Acute Hepatitis in an Immunocompetent Patient". The Journal of Infectious Diseases. 220 (6): 951–955. doi:10.1093/infdis/jiz025. ISSN 0022-1899. PMID 30649379.
59. Witte W., Kresken M., Braulke C., Cuny C. (1997). "Increasing incidence and widespread dissemination of methicillin-resistant Staphylococcus aureus (MRSA) in hospitals in central Europe, with special reference to German hospitals". Clinical Microbiology and Infection. 3 (4): 414–422. doi:10.1111/j.1469-0691.1997.tb00277.x. PMID 11864151.{{cite journal}}: CS1 maint: multiple names: authors list (link)
60. Benson M. A., Ohneck E. A., Ryan C., Alonzo F., Smith H., Narechania A., Torres V. J. (2014). "Evolution of hypervirulence by a MRSA clone through acquisition of a transposable element". Molecular Microbiology. 93 (4): 664–681. doi:10.1111/mmi.12682. PMC 4127135. PMID 24962815.{{cite journal}}: CS1 maint: multiple names: authors list (link)
61. ^ Krishnapillai V (1996). "Horizontal gene transfer". Journal of Genetics. 75 (2): 219–232. doi:10.1007/bf02931763. S2CID 5989957.
62. ^ Staff (16 July 2021). "WHO Director-General's opening remarks at the Member State Information Session on Origins". World Health Organization. Retrieved 27 September 2021.
63. Cohen J (17 July 2021). "With call for 'raw data' and lab audits, WHO chief pressures China on pandemic origin probe - A new team of scientists may replace agency group already probing the start of COVID-19". Science. Retrieved 27 September 2021.
64. Kupferschmidt K (25 August 2021). "New WHO group aims to improve efforts to find pathogen origins - The World Health Organization's Maria Van Kerkhove on the hunt for COVID-19 origins and what's next". Science. Retrieved 27 September 2021.
65. Staff (8 September 2021). "Deadline extension - call for experts to join the Scientific Advisory Group for the Origins of Novel Pathogens (SAGO)". World Health Organization. Retrieved 27 September 2021.

Further reading

• Nathan Wolfe (2012). The Viral Storm: The Dawn of a New Pandemic Age. St. Martin's Griffin. ISBN 978-1250012210.

External links

• Website of Emerging Infectious Diseases, an open-access, peer-review journal published by the Centers for Disease Control and Prevention (CDC)

• Infectious diseases
• Microbial population biology
• Infectious diseases by mode of transmission